Tapentadol Versus Oxycodone for Opioid-Related Adverse Drug Events and Clinical Outcomes After Inpatient Surgery

他喷他多 羟考酮 医学 类阿片 不利影响 麻醉 入射(几何) 内科学 物理 受体 光学
作者
Shania Liu,Asad E. Patanwala,Justine M. Naylor,Jennifer A. Stevens,Bernadette Bugeja,David Begley,Kok Eng Khor,Eric H. Y. Lau,Sam Adie,Jonathan Penm
出处
期刊:The Journal of Pain [Elsevier BV]
卷期号:25 (2): 466-475 被引量:5
标识
DOI:10.1016/j.jpain.2023.09.007
摘要

Oxycodone is a commonly prescribed opioid for postoperative pain. However, there has been a marked increase in the use of tapentadol over the previous decade due to a perceived superior safety profile of tapentadol compared to oxycodone. There is limited real-world evidence on the safety of tapentadol compared to oxycodone after surgery. The primary objective was to examine the impact of tapentadol compared to oxycodone use on the incidence of opioid-related adverse drug events after surgery. Data for adult surgical patients receiving tapentadol or oxycodone during hospitalization between January 1, 2018, and December 31, 2021, were collected from electronic medical records of 3 tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events. Patients receiving tapentadol or oxycodone were matched using nearest-neighbour propensity score matching. In the matched cohorts (n = 1,530 vs n = 2,775; mean [standard deviation] age 62.3 [17.0] years vs 61.9 [standard deviation 17.9] years; 43% vs 45% male for the tapentadol vs oxycodone groups, respectively), patients given tapentadol experienced a similar incidence of adverse events overall (14.4%, 220/1,530 vs 12.6%, 349/2,775; P = .100; 95% CI -.35% to 3.95%). Secondary outcomes included an increased risk of delirium (2.7%, 41/1,530 vs 1.3%, 37/2,775), arrhythmias (3.4%, 52/1,530 vs 2.2%, 62/2,775), and length of hospital stay (5 [range 1-201] vs 4 [range 1-226] days) compared with oxycodone use. Further real-world studies are warranted to determine the impact of tapentadol use on a broad range of patient outcomes. PERSPECTIVE: This study provides an early signal that tapentadol use may be associated with an increased risk of some adverse events and a longer length of stay. Further research is needed to examine the impact of tapentadol use on a broad range of patient outcomes in clinical practice settings.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大气灵枫发布了新的文献求助10
刚刚
5秒前
XXX完成签到 ,获得积分10
5秒前
7秒前
与光应助向言之采纳,获得10
10秒前
10秒前
GLCGLCGLCGLC完成签到,获得积分10
10秒前
FashionBoy应助WTH18732189630采纳,获得10
12秒前
可爱的函函应助科研小子采纳,获得10
14秒前
14秒前
零零落落发布了新的文献求助10
17秒前
熊大对熊二说熊要有个熊样完成签到,获得积分10
22秒前
cccc完成签到,获得积分10
22秒前
22秒前
可爱的函函应助moon采纳,获得10
22秒前
查资料完成签到 ,获得积分10
22秒前
wangyue1995完成签到,获得积分10
23秒前
慕青应助hzx采纳,获得20
24秒前
25秒前
26秒前
核桃发布了新的文献求助10
27秒前
29秒前
29秒前
jin完成签到,获得积分10
30秒前
ding应助零零落落采纳,获得10
30秒前
32秒前
怡然的秋柳完成签到,获得积分10
32秒前
核桃应助追寻的白安采纳,获得10
32秒前
Fn完成签到 ,获得积分10
32秒前
ll完成签到,获得积分10
34秒前
moon发布了新的文献求助10
34秒前
典雅起眸发布了新的文献求助10
35秒前
卓卓发布了新的文献求助10
37秒前
李健应助ASA采纳,获得10
38秒前
科研通AI2S应助Veson采纳,获得10
40秒前
热情曲奇完成签到,获得积分10
40秒前
桐桐应助moon采纳,获得10
41秒前
星辰大海应助森林木采纳,获得10
45秒前
ZTX完成签到,获得积分20
50秒前
轩辕沛柔完成签到,获得积分10
53秒前
高分求助中
(禁止应助)【重要!!请各位详细阅读】【科研通的精品贴汇总】 10000
Semantics for Latin: An Introduction 1099
Robot-supported joining of reinforcement textiles with one-sided sewing heads 800
水稻光合CO2浓缩机制的创建及其作用研究 500
Logical form: From GB to Minimalism 500
2025-2030年中国消毒剂行业市场分析及发展前景预测报告 500
The Netter Collection of Medical Illustrations: Digestive System, Volume 9, Part III – Liver, Biliary Tract, and Pancreas, 3rd Edition 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4169608
求助须知:如何正确求助?哪些是违规求助? 3704949
关于积分的说明 11691971
捐赠科研通 3391744
什么是DOI,文献DOI怎么找? 1860072
邀请新用户注册赠送积分活动 920239
科研通“疑难数据库(出版商)”最低求助积分说明 832631